(BGM) will help Cordex
Pharma with its Phase II trial of CDP-1050 in heart failure patients. The company will measure levels of Galectin-3 in patients enrolled in the study. Galectin-3 is a biomarker for cardiac remodeling associated with advanced stages of heart failure.
CDP-1050 targets the redox-nitric oxide imbalance, which is increasingly recognized as a major factor in poor myocardial contractile efficiency, Cordex points out.
The compound reportedly has a dual mechanism of action: It inhibits the production of excessive reactive oxygen radicals and restores nitric oxide to physiologic levels. The primary therapeutic target is the ryanodine receptor, the main ion channel in the heart that supplies the calcium necessary for the heart to contract.